Enrofloxacin nano-microemulsion solution for treating Mycoplasma synoviae disease in poultry

Abstract

The invention discloses an enrofloxacin nano-microemulsion solution for treating Mycoplasma synoviae disease in poultry. The nano-microemulsion is prepared by the following method: preparing raw materials including 5-15 parts by weight of enrofloxacin, 5-15 parts by weight of an oil phase, 5-20 parts by weight of a surfactant, 5-20 parts by weight of a cosurfactant, and 30-80 parts by weight of awater phase; adding enrofloxacin, the surfactant and the cosurfactant into a reaction device, and dispersing in a water phase through stirring, ultrasonic treatment or homogenization treatment to obtain an emulsion; slowly adding the emulsion into an oil phase, introducing nitrogen to expel oxygen, and adding a mixture of initiators; and carrying out external cooling and polymerization on the above reaction to obtain the enrofloxacin nano-microemulsion solution. The invention aims to provide an enrofloxacin nano-microemulsion solution for treating Mycoplasma synoviae disease in poultry. The process effect of adopting a nano-microemulsion preparation is more stable than the effect of a common oral solution, and the enrofloxacin nano-microemulsion solution shows a better therapeutic effect on Mycoplasma synoviae disease in poultry.

Description

technical field [0001] The invention relates to the technical field of veterinary preparations, in particular to an enrofloxacin nano-microemulsion solution for treating poultry mycoplasma synovialis disease. Background technique [0002] Enrofloxacin is a synthetic third-generation quinolone antibacterial drug, also known as ethyl ciprofloxacin, which was approved by FDA on October 4, 1996. It is a special quinolone antibacterial drug for livestock, poultry and aquatic products. It can bind to subunit A of bacterial DNA gyrase, thereby inhibiting the cutting and joining functions of the enzyme, preventing the replication of bacterial DNA, and exhibiting antibacterial effect. It has broad-spectrum antibacterial activity and strong permeability. This product is a broad-spectrum bactericidal drug, which has special effects on mycoplasma, strong killing effect on Gram-negative bacteria, and good antibacterial effect on Gram-positive bacteria. Function, good oral absorption, hi...

AI Technical Summary

Problems solved by technology

[0003] At present, commonly used enrofloxacin preparations mainly include solid granules, injections, etc., while ordinary injections have a short half-life and are eliminated rapidly in the body, requiring multiple administrations, which is time-consuming and laborious; the bioavailability of solid granules is low, which is not conducive to large-scale production. scale dosing

And because the preparations of many manufacturers do not have technology at all, so the same dosage, the clinical effect is uneven, the product quality is unstable, the bioavailability is not high, and the disadvantages such as large toxic and side effects